CN121152792A - 具有Nrf2活化作用的含氮杂环化合物的晶体 - Google Patents

具有Nrf2活化作用的含氮杂环化合物的晶体

Info

Publication number
CN121152792A
CN121152792A CN202480033461.0A CN202480033461A CN121152792A CN 121152792 A CN121152792 A CN 121152792A CN 202480033461 A CN202480033461 A CN 202480033461A CN 121152792 A CN121152792 A CN 121152792A
Authority
CN
China
Prior art keywords
crystal
powder
compound
diffraction
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202480033461.0A
Other languages
English (en)
Chinese (zh)
Inventor
岩田智哉
高田则幸
河野将人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN121152792A publication Critical patent/CN121152792A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN202480033461.0A 2023-06-19 2024-06-18 具有Nrf2活化作用的含氮杂环化合物的晶体 Pending CN121152792A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023100075 2023-06-19
JP2023-100075 2023-06-19
PCT/JP2024/022040 WO2024262491A1 (ja) 2023-06-19 2024-06-18 Nrf2活性化作用を有する含窒素複素環化合物の結晶

Publications (1)

Publication Number Publication Date
CN121152792A true CN121152792A (zh) 2025-12-16

Family

ID=93935419

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202480033461.0A Pending CN121152792A (zh) 2023-06-19 2024-06-18 具有Nrf2活化作用的含氮杂环化合物的晶体

Country Status (9)

Country Link
EP (1) EP4696692A1 (cg-RX-API-DMAC7.html)
JP (1) JP7904995B2 (cg-RX-API-DMAC7.html)
KR (1) KR20260023529A (cg-RX-API-DMAC7.html)
CN (1) CN121152792A (cg-RX-API-DMAC7.html)
AU (1) AU2024314540A1 (cg-RX-API-DMAC7.html)
IL (1) IL324833A (cg-RX-API-DMAC7.html)
MX (1) MX2025014082A (cg-RX-API-DMAC7.html)
TW (1) TW202504613A (cg-RX-API-DMAC7.html)
WO (1) WO2024262491A1 (cg-RX-API-DMAC7.html)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
US20190380992A1 (en) 2014-12-04 2019-12-19 Biogen Ma Inc. Multiple Sclerosis Treatment Regimen Using Dimethyl Fumarate
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
KR102932313B1 (ko) 2019-02-15 2026-02-26 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 활성화제로서 히드록시피리드옥사제핀
CN114174289B (zh) 2019-05-31 2025-03-07 Ube株式会社 苯并三唑衍生物
GB202005852D0 (en) 2020-04-22 2020-06-03 C4X Discovery Ltd Therapeutic compounds
CN114507181B (zh) 2020-11-17 2024-03-26 中国医学科学院药物研究所 含5-取代四氢异喹啉的丙酸类化合物、其药物组合物和应用
CR20240325A (es) 2022-01-07 2024-11-22 Chugai Pharmaceutical Co Ltd Compuesto heterocíclico que contiene nitrógeno que tiene un efecto de activación del nrf2

Also Published As

Publication number Publication date
TW202504613A (zh) 2025-02-01
JP7904995B2 (ja) 2026-08-13
IL324833A (en) 2026-01-01
MX2025014082A (es) 2026-01-07
AU2024314540A1 (en) 2025-11-27
KR20260023529A (ko) 2026-02-20
EP4696692A1 (en) 2026-02-18
JPWO2024262491A1 (cg-RX-API-DMAC7.html) 2024-12-26
WO2024262491A1 (ja) 2024-12-26

Similar Documents

Publication Publication Date Title
JP7773987B2 (ja) スピロ環含有キナゾリン化合物
CN109776445B (zh) 苯并噁二唑类化合物及其制备方法和医药用途
CN103694236B (zh) 一种嘧啶骨架具有刺猬通路拮抗剂活性的抗肿瘤化合物
TWI551595B (zh) 2,4-disubstituted benzene-1,5-diamine derivatives and their use, Its preparation of pharmaceutical compositions and pharmaceutical compositions
CN114685488A (zh) 作为sos1抑制剂的化合物及其应用
CN115894520A (zh) 一种大环k-ras g12c抑制剂及其制备方法和在药学上的应用
CN104341451B (zh) 新磷酸酯化合物、其制备方法及含有它们的药物组合物
WO2013134298A1 (en) Raf inhibitor compounds
ES2707726T3 (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
WO2023005267A1 (zh) 一种苯并[b]硒吩类STING调控剂、其制备方法及用途
CN103923085B (zh) 具有刺猬通路拮抗剂活性的吡啶杂环化合物及其用途
CN108727295A (zh) 一种2-(3-氨基苯基)-苯并噻唑衍生物及其制备方法和用途
AU2018340505A1 (en) Novel heterocyclic compounds as modulators of mGluR7
JP2025523030A (ja) Myt1阻害剤としての化合物
CN107245073A (zh) 4-(芳杂环取代)氨基-1h-3-吡唑甲酰胺类flt3抑制剂及其用途
CA3029911C (en) Antimetastatic 2h-selenopheno[3,2-h]chromenes, synthesis thereof, and methods of using same agents
AU2003217373A1 (en) Novel tyloindicines and related processes, pharmaceutical compositions and methods
KR100902145B1 (ko) 3,4-디히드로퀴나졸린 유도체 및 그를 포함하는 항암제조성물
CN104098457B (zh) 四氢姜黄素类似物及其制备和应用
CN103373986A (zh) 克里唑替尼前药及其制备方法与用途
AU2024314540A1 (en) Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect
CA3291766A1 (en) Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect
WO2022171088A1 (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
CN116217551B (zh) 取代的吲唑或氮杂吲唑类化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40127889

Country of ref document: HK